2017 Q1 report, January-March for Panion Animal Health

Q1 January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 267 (-).
  • Earnings per share: SEK -0,11 (-). 
  • Liquidity at the end of the period: kSEK 102 (582).

Significant events after the end of the period:

  • A shares emission running from 8 - 26 May has been successfully finalized.
  • A Letter of Intent has been signed with GeneQuine Biotherapeutics GmbH.
  • Annual Meeting was held 27/4 - the minutes and decisions are published on Panion's website.

CEO statement

During the first quarter of 2017, we have consolidated and prepared Panion for the exiting times ahead. The Board and the Management have settled in and are actively pushing forward our business plan. The procedures and development plans have matured and the company has been made ready to be listed on a market place. A small directed emission of shares facilitated this process.

At the time of writing this report, the emission of new shares to existing and new shareholders has just been finalized with a very satisfying result.

9% of Panions existing shareholders decided to increase their share holdings and in addition Panion managed to attract significant interest from new investors. After the share issue there are 1247 shareholders in Panion and with the new funds of MSEK 7,4 from the share issue, Panion is now well capitalized for the coming 12-18 months. The emission was successfully handled with the qualified assistance of our financial advisors from Regin Corporate Finance in Stockholm.

We have in Q1 continued the work on the epilepsy product for dogs in cooperation with CombiGene AB. Epilepsy in dogs is serious disease that affects millions of family dogs across the world and for which medicine is not effective in approximately 30% of cases. We want to develop an effective gene therapy treatment that can alleviate or eliminate the scary and unpleasant seizure attacks and improve the quality of life for these dogs and their owners. The license agreement that we have with CombiGene is now fully operational with a service and supply agreement connected to it. The Board has evaluated the market potentials and opening the process in USA will be the first move towards the realization of the potential of this very interesting product. A US office is established and our US agent in place for the FDA-procedures to progress smoothly. Moreover, we have two US-based specialized consultants connected to Panion and they are ready to help us move forward with the clinical development and approval of the epilepsy product for dogs.

In the meantime, we have continued the search for more in-licensing opportunities. The business model where we develop and commercialize the animal assets of new medicinal projects from the human field, remains the promising core of our strategy. Recently, the first step into a cooperation with the Germany-based company GeneQuine Biotherapeutics GmbH was taken by the mutual signing of a Letter of Intent. GeneQuine, which was established in 2012, develops gene therapy for osteoarthritis, a degenerative joint disease, in humans, horses, and dogs. They hold worldwide exclusive IP rights to specific gene therapy vectors and their use in the treatment of osteoarthritis. The Letter of Intent will facilitate discussions pertaining to a license agreement with regards to these novel veterinary medicines.

It is fantastic to see the company transform from a science based entity to a focused product development company with a clear direction, and I look forward to the coming steps and challenges.

Anja Holm,
vd, Panion Health AB

Future reporting dates
Interim Report for Q2 2017, 21 August 2017
Interim Report for Q3 2017, 21 November
Interim Report for Q4 2017, 22 February 2018

For the complete report, see attached document.

For further information, please contact:
Anja Holm, VD
Phone +45 22 94 66 00
E-mail: anja.holm@panion-animalhealth.com

More information is available at www.panion-animalhealth.com

Nerladdningsbara filer

2017 Q1 report, January-March for Panion Animal Health

Q1 January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 267 (-).
  • Earnings per share: SEK -0,11 (-). 
  • Liquidity at the end of the period: kSEK 102 (582).


Utfall i Panion's företrädesemission

Panion Animal Health AB (publ) ("Panion" eller "Bolaget") har slutfört den företrädesemission av aktier som beslutades med stöd av bemyndigande lämnat på bolagsstämma 27 april 2017. Teckningstiden löpte från och med 8 maj till den 26 maj 2017. Företrädesemissionen har tecknats till ca 60 % och tillför därmed Bolaget ca 7,4 MSEK före emissionskostnader.



Panion Animal Health and GeneQuine Biotherapeutics GmbH in novel veterinary medicine

Panion and GeneQuine has signed a mutual Letter of Intent to facilitate the discussions for a license agreement in the coming months with regards to novel veterinary medicine.


Panion accepted in EMA's SME-program

PANION Animal Health AB has successfully applied for and received the European Medicines Agency's (EMA's) SME status. The SME status is issued to Small and Medium-sized Enterprises (SMEs) who then can benefit from receiving administrative, regulatory and financial support via the SME office at EMA.


Panion förlägger sin kliniska utveckling i USA

Panion Animal Health AB ska genomföra kliniska tester av sin genterapeutiska läkemedelskandidat på hundar med epilepsi. Den största potentialen finns i USA och styrelsen har därför tagit initiativ för att utföra projektet där.



Kallelse till årsstämma i Panion Animal Health

Aktieägarna i Panion Animal Health AB (publ), org.nr 559018-4171 ("Bolaget") kallas härmed till årsstämma torsdagen den 27 april 2017 kl. 10.00 i Det gamla styrelserummet, byggnad 301, Medicon Village, Scheelevägen 2, Lund.


Year End Report and Quarterly Report October - December 2016-01-01 - 2016-12-31

Q4 October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -643 (-216).
  • Earnings per share: SEK -0.05 (-4.32).
  • Liquidity at the end of the period: kSEK 306 (84).

The period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -692 (-217).
  • Earnings per share: SEK -0.06 (-4.34).

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: